Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Research & Studies
Share your love
Oklahoma Doctor Wins $2.3M NIH for Retinopathy Research
Dr. Faizah Bhatti, a neonatologist and researcher from the University of Oklahoma, has been awarded a 5-year, $2.3 million grant from the National Institutes of Health (NIH) to investigate the role of surfactant protein A in the development of retinopathy…
Top 15 International Ophthalmology Congresses in 2024
As the field of ophthalmology continues to advance, a plethora of international congresses offer opportunities for professionals to explore the latest innovations, share insights, and foster collaborations. Here is a comprehensive list of the top 15 international ophthalmology conferences scheduled…
Tarsus Appoints Dr. Elizabeth Yeu as Chief Medical Officer
Tarsus Pharmaceuticals has announced the appointment of Elizabeth Yeu, MD, as Chief Medical Officer, effective November 4, 2024. Dr. Yeu, an esteemed ophthalmologist with over two decades of clinical and leadership experience, will lead the company’s medical organization and oversee…
Formosa: Positive Phase 3 Results for APP13007 in China
Formosa Pharmaceuticals recently announced the completion of CPN-303, a Phase 3 clinical trial conducted in Chinese cataract surgery patients to evaluate APP13007 (GPN00833). This trial, managed by Formosa’s licensee Grand Pharma (0512.HK), demonstrated positive top-line results, showcasing APP13007’s effectiveness in…
Neurotech FDA Update on NT-501 MacTel Treatment| OBN
Neurotech Pharmaceuticals has released an update regarding its biologics license application (BLA) for NT-501 (revakinagene taroretcel), a treatment designed for macular telangiectasia type 2 (MacTel). The U.S. Food and Drug Administration (FDA) has recently extended the Prescription Drug User Fee…
FDA Fast Tracks FLQ-101 for Retinopathy of Prematurity
The U.S. FDA has granted fast track designation to FLQ-101, FELIQS’ oral and intravenous solution targeting retinopathy of prematurity (ROP). This designation will accelerate the regulatory review process for FLQ-101, a promising treatment for a condition currently lacking approved preventative…
Santen, Arctic Vision to Launch ARVN001 in China
Clearside Biomedical has announced that Arctic Vision, its Asia-Pacific partner, has signed a commercial collaboration agreement with Santen Pharmaceutical Co. for ARVN001 (known in the United States as XIPERE) to treat uveitic macular edema (UME) and additional ophthalmic indications in…
Genentech: Vabysmo Effective for Diverse DME Patients
Genentech recently announced encouraging one-year results from its phase 4 ELEVATUM study evaluating Vabysmo (faricimab-svoa) for diabetic macular edema (DME) in racially and ethnically underrepresented populations. The findings, presented at the American Academy of Ophthalmology (AAO) 2024 annual meeting in…
FDA Clears HG202 CRISPR Therapy for Wet AMD Trials
The U.S. FDA has granted investigational drug clearance for HG202, a pioneering CRISPR/Cas13Y RNA-editing therapy developed by HuidaGene to treat neovascular (wet) age-related macular degeneration (AMD). This milestone makes HG202 the first CRISPR/Cas13Y RNA-targeting therapy in clinical development and the…
VSY Biotechnology Unveils Maestro® Sinusoidal IOL at ESCRS24
VSY Biotechnology to Complete Global Rollout of its Sinusoidal Vision Technology (SVT®) at ESCRS 2024 This year’s European Society of Cataract and Refractive Surgeons (ESCRS) 2024 kicked off with the highly anticipated third iNovation Day, which brought together the medical…